Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helio S Sader

Showing results (281-290 of 420) with videos related to

Pageof 42
Sort By:
Journal of Clinical Microbiology|September 28, 2018
Evaluation of the Revised Ceftaroline Disk Diffusion Breakpoints When Testing a Challenge Collection of Methicillin-Resistant Staphylococcus aureus IsolatesHelio S Sader, Paul R Rhomberg, Timothy B Doyle, et al.
Antimicrobial Agents and Chemotherapy|January 7, 2009
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolatesDouglas J Biedenbach, Jan M Bell, Helio S Sader, et al.
Antimicrobial Agents and Chemotherapy|January 9, 2019
Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016)Cecilia G Carvalhaes, Michael D Huband, Harald H Reinhart, et al.
International Journal of Antimicrobial Agents|June 22, 2005
Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) ProgramTamara R Anderegg, Helio S Sader, Thomas R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|August 18, 2005
Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continentsHelio S Sader, Ronald N Jones, Matthew G Stilwell, et al.
Diagnostic Microbiology and Infectious Disease|August 18, 2005
Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumoniaThomas R Fritsche, Helio S Sader, Matthew G Stilwell, et al.
Diagnostic Microbiology and Infectious Disease|May 10, 2005
Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum ProgramJames E Ross, Tamara R Anderegg, Helio S Sader, et al.
The Pediatric Infectious Disease Journal|September 16, 2014
Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012)Helio S Sader, Rodrigo E Mendes, David J Farrell, et al.
Antimicrobial Agents and Chemotherapy|November 22, 2017
<i>In Vitro</i> Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016)Michael A Pfaller, Rodrigo E Mendes, Leonard R Duncan, et al.
The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases|September 24, 2017
Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013-2015)Michael A Pfaller, Dee Shortridge, Helio S Sader, et al.
Pageof 42

Showing results (281-290 of 420) with videos related to

Sort By:
Pageof 42
Journal of Clinical Microbiology|September 28, 2018
Evaluation of the Revised Ceftaroline Disk Diffusion Breakpoints When Testing a Challenge Collection of Methicillin-Resistant Staphylococcus aureus IsolatesHelio S Sader, Paul R Rhomberg, Timothy B Doyle, et al.
Antimicrobial Agents and Chemotherapy|January 7, 2009
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolatesDouglas J Biedenbach, Jan M Bell, Helio S Sader, et al.
Antimicrobial Agents and Chemotherapy|January 9, 2019
Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016)Cecilia G Carvalhaes, Michael D Huband, Harald H Reinhart, et al.
International Journal of Antimicrobial Agents|June 22, 2005
Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) ProgramTamara R Anderegg, Helio S Sader, Thomas R Fritsche, et al.
Diagnostic Microbiology and Infectious Disease|August 18, 2005
Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continentsHelio S Sader, Ronald N Jones, Matthew G Stilwell, et al.
Diagnostic Microbiology and Infectious Disease|August 18, 2005
Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumoniaThomas R Fritsche, Helio S Sader, Matthew G Stilwell, et al.
Diagnostic Microbiology and Infectious Disease|May 10, 2005
Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum ProgramJames E Ross, Tamara R Anderegg, Helio S Sader, et al.
The Pediatric Infectious Disease Journal|September 16, 2014
Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012)Helio S Sader, Rodrigo E Mendes, David J Farrell, et al.
Antimicrobial Agents and Chemotherapy|November 22, 2017
<i>In Vitro</i> Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016)Michael A Pfaller, Rodrigo E Mendes, Leonard R Duncan, et al.
The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases|September 24, 2017
Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013-2015)Michael A Pfaller, Dee Shortridge, Helio S Sader, et al.
Pageof 42